A role for surgery in primary pancreatic B-cell lymphoma: a case report

This is an Open Access article distributed under the terms of the Creative Commons Attribution Licens

Qualidade de vida de pacientes com câncer de mama em terapia adjuvante

O objetivo do estudo foi avaliar a Qualidade de Vida (QV), identificar os domínios afetados em pacientes comcâncer de mama em terapia adjuvante e correlacioná-los com características sócio-demográficas, clínicas e terapêuticas.Estudo transversal, realizado com 35 pacientes entre agosto de 2007 e dezembro de 2008. Utilizou-se oinstrumento Quality of Life Core-30-Questionnaire (QLQ-C30). A Qualidade de Vida geral foi considerada poucosatisfatória. Os domínios afetados foram: função emocional, insônia, dor e fadiga. Nas correlações, as pacientesacima de 60 anos apresentaram pior escore na função emocional, as submetidas à cirurgia referiram mais constipação,as que realizavam radioterapia obtiveram pior escore para QV geral e as que estavam em quimioterapia hámais de seis ciclos apresentaram a função emocional afetada e dispnéia. Concluiu-se que os tratamentos adjuvantesafetaram de algum modo as pacientes, causando déficit na função emocional e relataram mais sintomas, prejudicandoassim sua QV

Results of a 7-day aprepitant schedule for the prevention of nausea and vomiting in 5-day cisplatin-based germ cell tumor chemotherapy

Purpose The purpose of this study was to determine the efficacy of adding a 7-day aprepitant schedule to a 5HT3 receptor antagonist and dexamethasone for patients with germ cell tumors receiving first-line 5-day cisplatin-based chemotherapy. Methods In a single-arm, open-label, multi-center, phase 2 trial, chemo-naive patients received aprepitant 125 mg PO (per oral) on day 1 and 80 mg PO on days 2 to 7, a 5HT3 receptor antagonist on days 1 to 5, and dexamethasone 8 mg on days 1 to 8. The primary endpoint was no emesis (vomiting or dry retching) during days 1 to 7 of cycle 1. Results Fifty patients were recruited. For cycle 1, proportions reporting no emesis on day 1, no emesis on days 1 to 7, no nausea on day 1, and no nausea on days 1 to 7 were 96, 82, 71, and 27 %, respectively. The efficacy was maintained in all cycles with over 80 % of patients reporting no emesis on any given day of any given cycle. Emesis was more common on days 4 to 7 (68 % episodes) than on days 1 to 3 (32 % episodes). Over any 24-h period, 49 % of patients with emesis reported no more than two episodes, and 62 % of patients with nausea reported intensity as 3 or less on a scale from 0 to 10. There were no unexpected or serious adverse events reported. Conclusion Adding 7 days of aprepitant to a 5HT3 receptor antagonist and dexamethasone effectively controlled acute and delayed emesis with 5-day cisplatin regimens. Days of nausea were more common than days of vomiting